Proxy Results (Form 8-K)

As previously disclosed, on August 18, 2026, 20/20 Biolabs, Inc. (the "Company") convened its annual meeting of stockholders of the Company (the "Annual Meeting"). At the Annual Meeting, the Company did not receive a sufficient number of votes with respect to Proposal 3 (Charter Amendment), so the Company adjourned the Annual Meeting with respect to Proposal 3 until September 16, 2026 at 10:00 a.m. Eastern Time (the "Adjourned Meeting").

Holders of shares of the Company's common stock at the close of business on June 22, 2026 were entitled to vote at the Adjourned Meeting. As of such date, there were 12,251,198 shares of common stock outstanding and entitled to vote. A total of 4,256,837 shares of common stock were represented in person or by valid proxies at the Adjourned Meeting, constituting a quorum.

The final results for the votes cast for Proposal 3 are set forth below. This Proposal is described in detail in the Company's definitive proxy statement, dated June 23, 2026, the relevant portions of which are incorporated herein by reference.

Proposal 3: The Company's stockholders approved an amendment and restatement of the Company's Second Amended and Restated Certificate of Incorporation to, among other things, increase the number of shares of common stock that the Company is authorized to issue from 50 million shares to 500 million shares. The votes regarding this proposal were as follows: